

Can individuals with low antibody responses to conventional antiviral vaccines acquire adequate antibody by the SARS-CoV-2 mRNA vaccine?

Short title: Responses to the SARS-CoV-2 mRNA vaccine of low responders to conventional vaccines

Wataru Ogura^{1¶}, Kouki Ohtsuka^{2¶*}, Sachiko Matsuura¹, Takahiro Okuyama¹, Satsuki Matsushima², Satoko Ymasaki², Hiroyuki Miyagi¹, Kumiko Sekiguchi¹, Hiroaki Ohnishi², Takashi Watanabe²

¹ Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo, Japan

² Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo, Japan

* Corresponding author

E-mail: kouki7@ks.kyorin-u.ac.jp (KO)

¶These authors contributed equally to this work.

Abstract

Objective

In Japan, healthcare workers (HCWs) are vaccinated against contagious viruses (measles, rubella, chickenpox, mumps, and hepatitis B) to prevent nosocomial infection. However, some do not produce sufficient antibodies after vaccination (low responders). Whether these low responders to conventional vaccines (live attenuated viruses or inactivated viruses) can produce adequate antibodies to mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains to be elucidated.

Methods

We conducted a prospective cohort study of 50 HCWs who received two doses of mRNA BNT162b2 vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, from before the first BNT162b2 vaccination to 5 months after the second vaccination. The antibody titers of low responders and normal responders were compared. In addition, SARS-CoV-2 neutralizing antibody activity was measured twice in low responders, 1 week to 1 month, and 5 months after the second vaccination.

Results

After vaccination, SARS-CoV-2 anti-spike antibody was detectable in the samples from low and normal responders at each timepoint. The median SARS-CoV-2 anti-spike antibody titer was higher in low responders than in normal responders 1 week after receiving the second dose of BNT162b2 vaccine (3721.0 vs 2251.5, $P=0.03$). Low responders had SARS-CoV-2 neutralizing antibody activity 1 week to 1 month, and 5 months after the second vaccination, which exceeded the positive threshold 5 months after the second vaccination.

Conclusion

After BNT162b2 vaccination, low responders acquired adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies to prevent SARS-CoV-2. These results suggest that vaccination with mRNA vaccine against SARS-CoV-2 should also be recommended for low responders to conventional vaccines.

Introduction

Coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic [1-4]. In view of the high number of cases of severe illness and death due to COVID-19, vaccination against SARS-CoV-2 infection is crucial.

SARS-CoV-2 has an enveloped, single, positive-stranded RNA genome that encodes four major viral structural proteins, namely, the nucleocapsid, spike, envelope, and membrane proteins; the latter three proteins are found in its membrane. The spike protein guides viral entry into host cells by binding to angiotensin-converting enzyme 2 (ACE2) receptors, which are widely expressed on epithelial cells and macrophages [5-7] and is thus an ideal target for messenger RNA (mRNA) vaccine development.

The BNT162b2 mRNA vaccine (Pfizer–BioNTech) is highly effective at preventing clinically significant COVID-19 [8-10], reducing the incidence of asymptomatic infection and associated infectivity [11,12], and preventing the spread of COVID-19 [9]. The BNT162b2 vaccine was the first SARS-CoV-2 vaccine to be approved in Japan, and priority vaccination of healthcare workers (HCWs) began in February 2021 in order to safeguard the medical delivery system [13].

HCWs also have a high risk of infection with other contagious viruses such as measles, rubella, chickenpox, mumps, and hepatitis B. Therefore, in Japan, HCWs are vaccinated against these viruses to prevent nosocomial infections and viral antibody titers are measured to ensure the presence of protective antibody levels [14]. Some individuals do not develop adequate antibody titers against contagious viruses even after vaccination. Such individuals are called low responders. It is unclear whether low responders to conventional vaccines can produce adequate SARS-CoV-2 antibodies, including neutralizing antibodies, after vaccination with the BNT162b2 vaccine to protect them against SARS-CoV-2 infection. Therefore, in this study we investigated whether low responders acquired SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies after vaccination with the BNT162b2 vaccine.

Materials and methods

Ethics consideration

We carried out a prospective cohort study of 50 HCWs. This study was conducted with the approval of the Ethics Committee of Kyorin University School of Medicine (Number R02-041; May 19, 2020). Informed consent was obtained from all study participants.

Subjects

The study was conducted at Kyorin University Hospital in Tokyo, Japan. HCWs at the hospital received two doses of BNT162b2 vaccine, 3 weeks apart. The participants were HCWs at the hospital who agreed to participate in the study and to

periodically donate blood samples before and after vaccination. Those whose antibody levels were below the standard values for preventing infection after receiving two or more doses of vaccine against measles, rubella, chickenpox, mumps, or hepatitis B viruses were classified as low responders.

SARS-CoV-2 anti-spike antibody assay

SARS-CoV-2 anti-spike antibody measurements were performed on serum obtained from centrifuged peripheral blood using the Elecsys Anti-SARS-CoV-2 S RUO (Roche Diagnostics International Ltd, Rotkreuz, Switzerland) on a Cobas 6000 (Roche Diagnostics) analyzer via the double-antigen sandwich enzyme-linked immunoassay method [15]. Samples were collected before the first dose of BNT162b2 vaccine was administered; 3 days after the first vaccination; 1, 2, and 3 weeks after the first vaccination; 1 week after the second vaccination; and 1, 2, 3, 4, and 5 months after the second vaccination. The measurement range of the antibody assay was 0.4–250, and samples with an antibody titer of ≥ 250 U/mL were assayed again after dilution.

SARS-CoV-2 neutralizing antibody assay

Using serum obtained from the peripheral blood of low responders after vaccination, SARS-CoV-2 neutralizing antibody activity was measured at Osaka University Microbial Disease Research Association Laboratory. A 50% inhibitory dilution factor (ID₅₀) using pseudovirus [16] was measured, and ID₅₀ values of ≥ 50 was considered positive [17]. For the neutralization assay, 60 μ L of pseudovirus, which is equivalent to 2.5×10^6 relative light units (RLU)/mL, was incubated with 60 μ L of serial

dilutions of serum samples for 1 h at 37°C. After incubation, 100 µL of the mixture was added to the Vero cells in a 96-well plate. The cells were lysed 24 h post-infection, luciferase was activated using the Luciferase Assay System (E1501, Promega, Wisconsin, USA), and RLU were measured using a Synergy LX analyzer (BioTek, USA). Percent neutralization was calculated using GraphPad Prism 8.0.2 (GraphPad Software, San Diego, California, USA). Percentages of RLU reduction (inhibition rate) were calculated as follows: $1 - (\text{RLU of sample sera} - \text{pseudovirus only wells}) / (\text{RLU from medium only wells} - \text{pseudovirus only wells}) \times 100\%$. The titers of neutralizing sera were calculated as ID₅₀. The transition of neutralizing antibody activity values after vaccination in low responders was examined 1 week to 1 month and 5 months after receiving the second dose of BNT162b2 vaccine.

Statistical analysis

Nonparametric continuous data are reported as median and interquartile range (IQR). The Mann–Whitney U test was performed to assess whether differences between cohorts were statistically significant. Two-sided *P*-values of <0.05 were considered statistically significant. The Wilcoxon matched-pairs signed rank test was performed to assess whether differences in antibody levels within an individual at different time points were statistically significant. Regarding the comparison of the age composition and gender of Low responders and Normal responders, the age composition (ratio of 20s to 40s and 50s to 60s) Fisher’s exact test was performed to test the age group and gender of low responders and normal responders for statistical significance. The Mann–Whitney U test was performed to test for statistically significant differences in antibody

levels of those aged 60s participants and total antibody levels of low responders and normal responders 1 week after the second vaccination. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [18]. Specifically, EZR is a modified version of R commander (version 1.54) that has been designed to add statistical functions frequently used in biostatistics.

Results

The low responders comprised three males (L1, L2, L4) with a negative (titer <16.0) anti-measles immunoglobulin G (IgG) antibody titer after measles virus vaccination and one female (L3) with a negative (titer <4.0) anti-mumps IgG antibody titer after mumps virus vaccination. Forty-six participants, comprising 12 males and 34 females, had antiviral antibody titers after vaccination against other viruses above the standard value (normal responders). The four low responders were aged 20s to 40s years. Normal responders were older than Low responders (the ratio of aged 50s to 60s years was 57% vs. 0%, respectively), but no significant difference was observed ($P > 0.99$). In addition, the gender difference (male/female ratio) was higher in females (74% vs. 15%), but no significant difference was observed ($P > 0.99$). All low responders were non-smokers and non-obese, and none of them had a history of taking immunosuppressive drugs or having a medical condition associated with immunodeficiency.

SARS-CoV-2 anti-spike antibody levels

The median (IQR) SARS-CoV-2 anti-spike antibody titer was 2251.5 (1639.0–3276.3) in the normal responders and 3721.0 (3255.0–4983.3) in the low responders 1 week after receiving the second dose of BNT162b2 vaccine. This difference was statistically significant ($P=0.03$). In the total antibody level 1 week after the second vaccination, 4% of the total was in the aged 60s, and there was no significant difference in the median antibody levels between the aged 60s and 20s to 50s years ($P=0.90$).

The median (IQR) SARS-CoV-2 anti-spike antibody in normal responders was 2251.5 (1639.0–3276.3) and 779.3 (534.6–1024.3) measured 1 week and 5 months, respectively, after receiving the second dose of BNT162b2 vaccine. In low responders, the median (IQR) SARS-CoV-2 anti-spike antibody was 3721.0 (3255.0–4983.3) and 666.7 (578.9–880.6) measured 1 week and 5 months, respectively, after receiving the second dose of BNT162b2 vaccine.

SARS-CoV-2 anti-spike antibody was produced by both low and normal responders, but the level was lower at 5 months than at 1 week after the second dose of vaccine (Table 1 and Fig 1A).

Table 1. SARS-CoV-2 anti-spike antibody responses in the study participants before and after vaccination with the BNT162b2 mRNA vaccine according to time since vaccination and their antibody responses to previous antiviral vaccines.

Time since vaccination	Normal responders (n=46)	Low responders (n=4)
	Median (IQR) U/mL	Median (IQR) U/mL

Before the first vaccination		0.4 (0.4–0.4)	0.4 (0.4–0.4)
After the first vaccination	3 days	0.4 (0.4–0.4)	0.4 (0.4–0.4)
	1 week	0.4 (0.4–0.4)	0.4 (0.4–0.4)
	2 weeks	16.9 (7.9–42.0)	18.0 (11.7–35.5)
	3 weeks	74.7 (28.3–130.0)	112.7 (60.2–159.2)
After the second vaccination	1 week	2251.5 (1639.0–3276.3)	3721.0 (3255.0–4983.3)
	1 month	1228.5 (977.7–1774.0)	1735.5 (1456.0–2121.8)
	2 months	1140.0 (845.8–1517.3)	1316.0 (1065.5–1857.5)
	3 months	983.9 (708.8–1367.0)	1008.3 (862.0–1353.3)
	4 months	912.1 (621.1–1192.8)	832.0 (741.0–1111.1)
	5 months	779.3 (534.6–1024.3)	666.7 (578.9–880.6)

The normal responders had normal antibody responses to previous antiviral vaccines.

The low responders had low antibody responses to previous measles or mumps and hepatitis B vaccines.

IQR: interquartile range

Fig 1. SARS-CoV-2 anti-spike antibody responses in- the study participants before and after vaccination with the BNT162b2 vaccine according to their antibody responses to previous antiviral vaccines.

(A) SARS-CoV-2 anti-spike antibody responses over the whole study period from before the first dose to 5 months after the second dose of vaccine.

(B) SARS-CoV-2 anti-spike antibody titers in normal responders 1 week and 5 months after receiving the second dose of BNT162b2 vaccine. The antibody titers were significantly lower at 5 months than at 1 week after the second dose ($P<0.001$).

(C) SARS-CoV-2 anti-spike antibody titers in low responders 1 week and 5 months after receiving the second dose of BNT162b2 vaccine. The antibody titers decreased, but the decrease was not statistically significant ($P=0.13$).

The box plot comparisons were performed using the Mann–Whitney U test. P -values <0.05 were considered statistically significant. Low responders had low-level antibody responses to previous measles or mumps vaccines, and normal responders had normal antibody responses to previous antiviral vaccines.

NaN; not a number

SARS-CoV-2 neutralizing antibody activity in participants with low-level antibody responses to previous antiviral vaccines

SARS-CoV-2 neutralizing antibody titers were 1154.0 in L1 at 1 week after receiving the second dose of BNT162b2 vaccine and 774.2, 638.3, and 654.6 in L2, L3, and L4, respectively, at 1 month after receiving the second dose of BNT162b2 vaccine. In the 5 months after the second vaccination, SARS-CoV-2 neutralizing antibody titers were 105.5, 147.7, 485.2, and 894.4 in L1, L2, L3, and L4, respectively. All four low responders had neutralizing antibody activity within the protective range from the 1 week to 1 month and 5 months after the second vaccination (Table 2 and Fig 2). The SARS-CoV-2 neutralizing antibody level in low responders was lower at 5 months after receiving the second dose of BNT162b2 vaccine than at 1 week to 1 month after receiving the second dose, but this difference was not statistically significant ($P=0.38$).

Table 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose of BNT162b2 vaccine in participants with low-level responses to previous antiviral vaccines.

Time since the second vaccination	ID ₅₀				
	L1	L2	L3	L4	Median
1 week to 1 month	1154.0	774.2	638.3	654.6	714.4
5 months	105.5	147.7	485.2	894.4	316.5

Data are presented as 50% inhibitory dilutions (ID₅₀). L1, L2, L3, and L4 represent four separate individuals with low antibody responses to previous antiviral (mumps or measles) vaccines.

Fig 2. SARS-CoV-2 neutralizing antibody activity responses after the second dose of BNT162b2 vaccine in participants with low-level antibody responses to previous antiviral vaccines.

Data are presented as 50% inhibitory dilutions (ID₅₀). The dashed line indicates the cutoff for ID₅₀ [17].

Discussion

The BNT162b2 vaccine has been highly effective in preventing clinically significant COVID-19 [8-10]. However, limited information is available about the effectiveness of the BNT162b2 vaccine in low responders to conventional vaccines. In

this study, low responders produced adequate SARS-CoV-2 anti-spike antibodies and neutralizing antibodies.

Muik et al. [19] measured the neutralization efficacy of sera from 40 healthy German subjects immunized with the BNT162b2 vaccine and a 50% inhibitory dilution factor using pseudovirus according to the same method as was used in this study. The SARS-CoV-2 neutralizing activity of the low responders in this study 1 week to 1 month after receiving the second dose of BNT162b2 vaccine was comparable to that of the participants in the German study. All four low responders developed protective levels of neutralizing antibodies. The SARS-CoV-2 neutralizing antibody activity value in the fifth month after the second dose of BNT162b2 vaccine did not show a significant decrease in activity compared with that 1 week to 1 month after receiving the second dose of BNT162b2 vaccine. The SARS-CoV-2 anti-spike antibody titer was lower at 5 months after the second dose of BNT162b2 vaccine than at 1 week after the second dose, but the decrease was not statistically significant in low responders. These results suggest that mRNA vaccines can invoke a protective immune response even in low responders who do not develop adequate antibody titers against viruses in response to conventional vaccines against viral diseases such as mumps and measles.

Measles, rubella, chickenpox, and mumps vaccines are live attenuated vaccines that weaken the toxicity of pathogenic microorganisms, and hepatitis B vaccines are

inactivated vaccines that cause pathogenic microorganisms to lose their ability to infect [20]. In previous studies, approximately 2%–10% of healthy individuals do not produce protective antibody levels in response to viral vaccines [21,22]. The risk factors for low response to these conventional viral vaccines include male sex, age of >40s, smoking habit, obesity, chronic diseases, and genetic factors. However, the factors associated with a low antibody response to SARS-CoV-2 mRNA vaccines are not well understood. Smokers, patients with cancer and hematological malignancies, and organ transplant recipients have been reported to have a lower SARS-CoV-2 anti-spike antibody response than individuals without these characteristics after receiving SARS-CoV-2 vaccines [23-26]. It is unknown why the low responders in this study did not produce adequate antibody against measles or mumps and yet produced adequate SARS-CoV-2 anti-spike antibody after receiving the BNT162b2 vaccine. They were healthy and did not have risk factors such as an organ transplant and immunosuppression. One possible reason for this discrepancy is the different mechanism of antibody production between conventional vaccines and SARS-CoV-2 mRNA vaccines.

The BNT162b2 vaccine is an mRNA vaccine, which incorporates mRNA encoding spike protein (antigen) on the surface of the SARS-CoV-2 into human cells, produces antigens and uses them to induce the acquired immune system [27]. The exact factors determining the production of SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibody activity in low responders after receiving live attenuated or inactivated vaccinations against viruses other than SARS-CoV-2 are unknown. With live attenuated vaccines or inactivated vaccines, it is necessary for recipients to process the vaccine and recognize it as an antigen, whereas with mRNA vaccines, the mRNA incorporated into the cell directly functions as a template for viral antigen. The

difference in the mechanism of action of vaccines could be a factor contributing to adequate response to the BNT162b2 vaccine among low responders to conventional live attenuated vaccines. Such hypothesis should be tested in future studies. It is also unclear why low responders had higher antibody titers than normal responders in the first week after the second dose of vaccine.

Of note, the SARS-CoV-2 anti-spike antibody level is known to peak and then decrease within months after the second vaccination, which is a much shorter period than that of antibodies against live attenuated vaccines [28,29]. In order to achieve adequate COVID-19 disease control, a third dose of SARS-CoV-2 mRNA vaccine is needed, which is already being administered in many countries [28]. Therefore, we recommend that both low and normal responders to conventional vaccines receive a third dose of the BNT162b2 vaccine.

This study has some limitations. The number of participants was limited, and all participants were HCWs vaccinated at a single hospital. In addition, there were no low responders to inactivated vaccines (such as hepatitis B) included in this study. Multicenter studies with a larger sample size are needed. In individuals with low antibody response to other viral vaccines, the mechanism by which humoral immunity is acquired after mRNA vaccination needs to be clarified through future research.

In conclusion, after two doses of the BNT162b2 vaccine, low responders to conventional antiviral vaccines developed protective levels of SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies. These results suggest that vaccination with

mRNA vaccine against SARS-CoV-2 should also be recommended to low responders against conventional vaccines.

Acknowledgments

We thank the HCWs of the Department of Clinical Laboratory, Kyorin University Hospital involved in the SARS-CoV-2 antibody monitoring for their valuable contribution.

References

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Baker SC, Baric RS, de Groot RJ, Drosten C, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020;5: 536-544. doi: [10.1038/s41564-020-0695-z](https://doi.org/10.1038/s41564-020-0695-z).
2. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. *Nature.* 2020;579: 265-269. doi: [10.1038/s41586-020-2008-3](https://doi.org/10.1038/s41586-020-2008-3).
3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 2020;579: 270-273. doi: [10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7).
4. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020;382: 727-733. doi: [10.1056/NEJMoa2001017](https://doi.org/10.1056/NEJMoa2001017).

5. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, Thrusting coronaviruses into the spotlight. *Viruses*. 2019;11: 59. doi: [10.3390/v11010059](https://doi.org/10.3390/v11010059).
6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181: 271-280.e8. doi: [10.1016/j.cell.2020.02.052](https://doi.org/10.1016/j.cell.2020.02.052).
7. Jiang S, Lu L, Liu Q, Xu W, Du L. Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. *Emerg Microbes Infect*. 2012;1: e13. doi: [10.1038/emi.2012.1](https://doi.org/10.1038/emi.2012.1).
8. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet*. 2021;397: 1819-1829. doi: [10.1016/S0140-6736\(21\)00947-8](https://doi.org/10.1016/S0140-6736(21)00947-8).
9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383: 2603-2615. doi: [10.1056/NEJMoa2034577](https://doi.org/10.1056/NEJMoa2034577).
10. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. *N Engl J Med*. 2021;384: 1412-1423. doi: [10.1056/NEJMoa2101765](https://doi.org/10.1056/NEJMoa2101765).
11. Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, et al. Decreased infectivity following BNT162b2 vaccination: a prospective cohort

- study in Israel. *Lancet Reg Health Eur.* 2021;7: 100150. doi: [10.1016/j.lanepe.2021.100150](https://doi.org/10.1016/j.lanepe.2021.100150).
12. Petter E, Mor O, Zuckerman N, Oz-Levi A, Younger A, Aran D, et al. Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. Preprint; 2021. doi: [10.1101/2021.02.08.21251329](https://doi.org/10.1101/2021.02.08.21251329).
 13. Pharmaceuticals and Medical Devices Agency. Special Approval for Emergency on first COVID-19 vaccine in Japan [media release]. 2021. Available from: [pmda.go.jp](https://www.pmda.go.jp).
 14. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. *Epidemiol Infect.* Cambridge University Press. 2014;142: 12-19. doi: [10.1017/S0950268813000393](https://doi.org/10.1017/S0950268813000393).
 15. Riestter E, Findeisen P, Hegel JK, Kabesch M, Ambrosch A, Rank CM, et al. Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay. *J Virol Methods.* 2021;297: 114271. doi: [10.1016/j.jviromet.2021.114271](https://doi.org/10.1016/j.jviromet.2021.114271).
 16. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. *Nat Protoc.* 2020;15: 3699-3715. doi: [10.1038/s41596-020-0394-5](https://doi.org/10.1038/s41596-020-0394-5).
 17. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature.* 2021;590: 630-634. doi: [10.1038/s41586-020-03041-6](https://doi.org/10.1038/s41586-020-03041-6).


18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZ’ for medical statistics. *Bone Marrow Transplant*. 2013;48: 452-458. doi: [10.1038/bmt.2012.244](https://doi.org/10.1038/bmt.2012.244).
19. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 Pseudovirus by BNT162b2 vaccine-elicited human sera. *Science*. 2021;371: 1152-1153. doi: [10.1126/science.abg6105](https://doi.org/10.1126/science.abg6105).
20. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020;586: 516-527. doi: [10.1038/s41586-020-2798-3](https://doi.org/10.1038/s41586-020-2798-3).
21. Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do? *Hum Vaccin Immunother*. 2016;12: 239-243. doi: [10.1080/21645515.2015.1093263](https://doi.org/10.1080/21645515.2015.1093263).
22. Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. *Br J Haematol*. 2022;196: 884-891. doi: [10.1111/bjh.17918](https://doi.org/10.1111/bjh.17918).
23. Nomura Y, Sawahata M, Nakamura Y, Kurihara M, Koike R, Katsube O, et al. Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. *Vaccines (Basel)*. 2021;9: 1042. doi: [10.3390/vaccines9091042](https://doi.org/10.3390/vaccines9091042).
24. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J Hematol*. 2021;96: 1195-1203. doi: [10.1002/ajh.26284](https://doi.org/10.1002/ajh.26284).

25. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, Del Molino Del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol.* 2021;22: 765-778. doi: [10.1016/S1470-2045\(21\)00213-8](https://doi.org/10.1016/S1470-2045(21)00213-8).
26. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. *Nat Med.* 2021;27: 2002-2011. doi: 10.1038/s41591-021-01542-z.
27. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A. Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. *Infect Drug Resist.* 2021;14: 3459-3476. doi: [10.2147/IDR.S315727](https://doi.org/10.2147/IDR.S315727).
28. Israel A, Merzon E, Schäffer AA, Shenhar Y, Green I, Golan-Cohen A, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. Preprint. medRxiv. 2021. doi: [10.1101/2021.08.03.21261496](https://doi.org/10.1101/2021.08.03.21261496)..
29. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N Engl J Med.* 2021;385: e84-e84. doi: [10.1056/NEJMoa2114583](https://doi.org/10.1056/NEJMoa2114583).

$P=\text{NaN}$ $P=\text{NaN}$ $P=0.71$ $P>0.99$ $P=0.54$ $P<0.05$ $P=0.15$ $P=0.34$ $P=0.78$ $P=0.99$ $P=0.90$

medRxiv preprint doi: <https://doi.org/10.1101/2021.12.26.21268358>; this version posted February 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

SARS-CoV-2 anti-spike antibody (U/mL)



After the first vaccination

After the second vaccination

before the first vaccination

3 days

1 week

2 weeks

3 weeks

1 week

1 month

2 months

3 months

4 months

5 months

